Organic brain syndrome treated with oxiracetam. A double-blind randomized controlled trial.
In a 12-week double-blind study, oxiracetam (CGP 21690 E), a new nootropic drug, at a dose of 2.4 mg per day, was compared to placebo in the treatment of 106 middle-aged patients suffering from mild to moderate organic brain syndrome due to prolonged exposure to organic solvents. At the beginning of the study and after 12 weeks treatment, the patients underwent a battery of neuropsychological tests to determine their mental and memory functioning. A symptom questionnaire consisting of 21 items was rated pre-treatment, and improvement or worsening of any of the symptoms recorded monthly. At the end of the study a global evaluation was performed by the patients themselves, their relatives, the psychologist and the doctor. The code was not broken until the final writing of this paper. No statistically significant differences were observed between the treatment groups in any of the above-mentioned evaluations; neither were any differences in the neuropsychological tests performance observed. Thus, oxiracetam seems to have no effect in the treatment of organic brain syndrome.
Hjorther
A
A
Browne
E
E
Jakobsen
K
K
Viskum
P
P
Gyntelberg
F
F
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007858:Learning / Q000187:drug effects; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D009483:Neuropsychological Tests; D011597:Psychomotor Performance / Q000187:drug effects; D011759:Pyrrolidines / Q000627:therapeutic use*; D011897:Random Allocation; D011795:Surveys and Questionnaires
D011759:Pyrrolidines; C040619:oxiracetam